February 10, 2025 12:31 PM GMT President Trump proposed 25% tariffs on aluminum & steel. If implemented, a lack of domestic production in Ali could lead to higher physical premiums. In steel, tougher tariffs may raise prices but low local utilization rates could keep a lid on gains. What's new? President Trump has discussed potential 25% tariffs on all steel and aluminum over the weekend, to be officially announced today (Feb 10th). This follows a speech made to the House Republicans on January 27th, in whi ...

Summary of Alnylam Pharmaceuticals Conference Call Company Overview - **Company**: Alnylam Pharmaceuticals - **Event**: 43rd Annual J.P. Morgan Healthcare Conference - **Date**: January 13, 2025 - **CEO**: Yvonne Greenstreet, MBChB Key Industry Insights - **Industry Focus**: RNAi Therapeutics - **Market Position**: Alnylam aims to be a top-tier biotech company with a strong focus on innovative RNAi therapeutics Core Points and Arguments 1. **Alnylam P5x25 Goals**: The company aspires to achieve its "Alnylam P5x25" goals, which include advancing multiple drug development candidates and achieving significant commercial milestones by 2025 [3][4] 2. **Product Pipeline**: Over 25 high-value programs are expected to be in clinical stages across diverse indications by the end of 2025 [5] 3. **Financial Performance**: - 33% year-over-year growth in net product revenue, reaching $1,646 million in 2024 [8][9] - Projected revenue compound annual growth rate (CAGR) of at least 40% through the end of 2025 [8] - Guidance for 2025 net product revenue between $2,050 million and $2,250 million, with expectations of achieving non-GAAP profitability [53][56] 4. **AMVUTTRA (Vutrisiran)**: - Positioned as a potential first-line treatment for ATTR-CM, with a PDUFA date set for March 23, 2025 [54][39] - Expected to capture significant market share due to favorable pricing and reimbursement dynamics [4][36] 5. **Clinical Advancements**: - Positive Phase 3 HELIOS-B results for vutrisiran, demonstrating significant improvements in mortality and cardiovascular outcomes [24][26] - Nucresiran (ALN-TTRsc04) shows promise with over 95% TTR knockdown and biannual or annual dosing [41][40] 6. **Market Opportunity**: - Over 300,000 patients globally suffer from ATTR amyloidosis, with approximately 80% undiagnosed [19] - The company is focused on driving earlier diagnosis and establishing AMVUTTRA as the first-line choice for treatment [30][29] Additional Important Insights 1. **Regulatory Strategy**: Alnylam is pursuing rapid global regulatory filings for its products, with multiple launches expected in 2025 [39] 2. **Cultural Recognition**: The company has maintained a strong corporate culture, recognized for its award-winning environment [9] 3. **Strategic Collaborations**: Alnylam relies on partnerships with major pharmaceutical companies for the development and commercialization of certain products [4] 4. **Long-term Goals**: The company aims to achieve sustainable non-GAAP profitability and expand its product offerings significantly by 2025 [57] Conclusion Alnylam Pharmaceuticals is positioned for significant growth in the RNAi therapeutics market, with a robust pipeline, strong financial performance, and a clear strategy for expanding its market presence. The upcoming regulatory approvals and clinical advancements are critical to achieving its ambitious goals.

6 January 2025 Aluminium Sector Equities A rough start to 2025 China Alumina future price slumps, indicating that supply is no longer in deficit As we expected, the alumina future price has declined by over 10% since the beginning of 2025 to cRMB4,250 (vs. an average price of RMB3,800 in 2024 and RMB3,100 in 2023), indicating that the supply shortage has started to ease as 1) demand declines in the traditional off season before Chinese New Year (CNY); and 2) a resumption of Rio Tinto's capacity and ramping ...

更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 January 2, 2025 02:28 AM GMT China Autos & Shared Mobility | Asia Pacific M Update All's well that ends well; all eyes are on air pocket in demand post subsidies China's major EV brands posted record Dec sales. BYD and XPeng beat market expectations on faster ramp-up of new models; while Li Auto and ZEEKR sales were slightly shy of their previous guidance. NIO reclaimed sales momentum, stretching to meet 4Q sales guidance. December hit a good balance between order intake and sel ...

M Update may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market ind ...

shuinu9870 shuinu9870 更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 shuinu9870 shuinu9870 更多一手调研纪要和研报数据加V： 更多一手调研纪要和研报数据加V： shuinu9870 更多一手调研纪要和研报数据加V： shuinu9870 更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 更多一手调研纪要和研报数据加V： shuinu9870 shuinu9870 shuinu9870 更多一手调研纪要和研报数据加V： shuinu9870 shuinu9870 shuinu9870 更多一手调研纪要和研报数据加V： 更多一手调研纪要和研报数据加V： North America Economic Research US: Already good 3Q GDP gets a little better 19 December 2024 J P M O R G A N shuinu9870 shuinu9870 更多一手调研纪要和研报数据加V： shuinu9870 更多一手调研纪要和研报数据加V： 更多一手调研纪要和研报数据加V： 更多资料加入知识星 ...

shuinu9870 Exhibit 8 - Recent & Forecasted Results as a % of Rolling 10-Yr Average - Advisory . 80% 100% 120% 140% 0% 20% 40% 60% . 0% 20% 40% 60% 80% 100% 120% 140% 160% 180% shuinu9870 Source: Company data, Jefferies, Visible Alpha Consensus as of 12/17/24 for JPM/BAC/C, JEFe for GS/MS Reopening of Capital Markets Critical for Alts - Much of the Alternative's expected ~27% distributable earnings growth in 2025 hinges on the reopening of capital markets. Years of subdued capital markets activity and depres ...

Investment Rating - The report does not explicitly provide an investment rating for the medtech industry in relation to the EU AI Act Core Insights - The EU AI Act is the world's first comprehensive AI law aimed at building trust in AI technologies while managing associated risks [7][11] - The Act introduces a regulatory framework that categorizes AI systems into four risk levels: unacceptable, high, limited, and minimal risk [25][26] - Medtech companies must comply with the AI Act, which influences their compliance responsibilities and financial interests, especially for high-risk AI applications [16][17] Chapter Summaries Chapter 1: A Need for New Rules - The AI Act aims to recognize and manage risks associated with AI applications, establish requirements for high-risk AI systems, and enforce compliance [13][14][16] - The Act is essential for medtech companies as it influences their compliance responsibilities and safeguards their financial interests [16][18] Chapter 2: Understanding the AI Act - The AI Act sets parameters for the development and use of AI in healthcare, promoting human-centric and trustworthy AI while ensuring high levels of health and safety protection [22][24] - The Act will initially reform general-purpose AI systems and later extend to AI-enabled digital health tools [22] Chapter 3: Risk Classification Under the AI Act - AI systems are classified into four risk categories: unacceptable risk (banned), high risk (subject to strict regulations), limited risk (transparency obligations), and minimal risk (no mandatory obligations) [25][26][38] - High-risk AI systems in medtech include medical devices and emergency triage systems, which must adhere to specific obligations before market entry [32][34] Chapter 4: Existing Regulation Overlaps with the Act - The AI Act overlaps with existing regulations like the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), leading to confusion among medtech professionals [42][43] - Medtech manufacturers may need to update their technical documentation to align with the new stipulations of the AI Act while navigating the complexities of overlapping regulations [46][49] Chapter 5: Stay on Top of the Evolving AI Landscape with AlphaSense - The report emphasizes the importance of market intelligence platforms like AlphaSense for medtech companies to stay informed about developments, legislation, and competition in the evolving AI landscape [60][62] Chapter 6: Looking Forward - The introduction of the AI Act is seen as essential for safeguarding consumers and providers in the healthcare sector, requiring medtech developers to navigate complex regulations [68][69]

Renewable Energy Trends & Outlook for 2024 AlphaSense What's Inside 1 Introduction 2 CHAPTER 1 What's Driving Interest In Renewable Energy? 4 CHAPTER 2 Renewable Energy Trends Around the World 9 CHAPTER 3 Growing Competition for Renewable Resources 10 CHAPTER 4 Renewable Energy Outlook for 2024 10 How to Stay On Top of Renewable Energy Trends 1 Introduction Since 2022, the oil industry has faced a series of volatile macroeconomic events that have escalated the importance of renewable energy. As societal con ...